New Analyses from the IMPROVE-IT Outcomes Study of VYTORINÂ® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIAÂ® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress